Kazia Therapeutics Limited (KZIA)
Nasdaq · Healthcare · Biotechnology
$9.35+0.86%as of Oct 6, 2026, 1:35 AM ET
- Market cap
- $107M
- 52-week range
- $4.86 – $17.40
- 52-week change
- +29.83%
- EPS (trailing)
- −$6.85
- Analyst rating
- 1.3 Strong buy
About Kazia Therapeutics Limited
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children's Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute.
Headquarters: Sydney, Australia · 6 employees · kaziatherapeutics.com